Eli Lilly's CEO, David Ricks, announced in Paris on Thursday that the shortage of the company's injectable GLP-1 product will end "soon," stating, "I think actually today or tomorrow we plan to exit that process." In response to this news, Hims & Hers Health, which had recently introduced compounded versions of Novo Nordisk's weight loss therapy, semaglutide, saw a significant drop in its stock.

Related Videos :

GLP 1 Weight Loss #nutritiontips #weightlossmedication #glp1 #dietitian #blackdietitian #diabetes [N6ycHQL4W]
Luke Newton and nicola coughlan on Colin BRIDGERTON's biggest ick🤢👀 #britishroyal #interview #news [Gn6j882Su]
3 Detox Water Recipes for Fast Weight Loss in Hindi | Weight Loss Detox Drink | summer infused water [Tv5maIgzz]
Adele Shows Off Her Weight Loss As Vogue’s March Cover Model [r9p9lCG6e]
Ajmer Dargah Par Kardia Gaya Shiv Mandir Hone Ka Dawa, Court Me Gaya Case, Milgayi Khadim Ko Notice [9tHmIBV9b]

Eli Lilly CEO announces resolution of weight loss drug shortage; HIMS takes a hit #HIMS #LLY #GLP1 [cheJ2gJNx]

Eli Lilly's CEO, David Ricks, announced in Paris on Thursday that the shortage of the company's injectable GLP-1 product will end "soon," stating, "I think actually today or tomorrow we plan to exit that process." In response to this news, Hims & Hers Health, which had recently introduced compounded versions of Novo Nordisk's weight loss therapy, semaglutide, saw a significant drop in its stock.